Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ SPINE,SPORTS & OTHER — Sales to Customers

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Stryker logo
SYKSpine — Net Sales
$2M-98.8%
Orthofix Medical Inc. logo
OFIXGlobal Spine — Revenue
$163.85M0.0%
OrthoPediatrics logo
KIDSSports medicine/other — Net revenue
$875K-0.6%
Globus Medical logo
GMEDMusculoskeletal Solutions — Net Sales
$732.98M+27.3%
Stryker logo
SYKOrthopaedics: — Net Sales
$2.81B+0.1%
Stryker logo
SYKOther Orthopedics — Net Sales
$157M+18.0%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's spine,sports & other — sales to customers.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's SPINE,SPORTS & OTHER — sales to customers?
Johnson & Johnson (JNJ) reported SPINE,SPORTS & OTHER — sales to customers of $713M in Q4 2025.
How has Johnson & Johnson's SPINE,SPORTS & OTHER — sales to customers changed year-over-year?
Johnson & Johnson's SPINE,SPORTS & OTHER — sales to customers decreased by 2.5% year-over-year, from $731.5M to $713M.
What is the long-term trend for Johnson & Johnson's SPINE,SPORTS & OTHER — sales to customers?
Over 4 years (2021 to 2025), Johnson & Johnson's SPINE,SPORTS & OTHER — sales to customers has grown at a -0.4% compound annual growth rate (CAGR), from $2.9B to $2.85B.
What does SPINE,SPORTS & OTHER — sales to customers mean?
This metric represents the total revenue generated from the sale of products within the spine, sports medicine, and related medical device categories. It reflects the market demand and commercial performance of these specialized orthopedic and surgical product lines. Monitoring this figure helps investors assess the growth trajectory and competitive positioning of the company's specialized medical device portfolio.